{"id":"ivig-peg","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Thrombotic events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IVIG-PEG combines standard intravenous immunoglobulin (IVIG) with polyethylene glycol (PEG) conjugation to prolong circulating half-life and reduce dosing frequency. The PEG modification allows for less frequent administration while maintaining therapeutic antibody levels. This approach is intended to improve patient convenience and compliance in immunodeficiency and autoimmune conditions.","oneSentence":"IVIG-PEG is a polyethylene glycol-conjugated intravenous immunoglobulin that provides passive immune protection by delivering pooled human antibodies with extended half-life.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:35.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders"},{"name":"Secondary immunodeficiency conditions"}]},"trialDetails":[{"nctId":"NCT01596335","phase":"PHASE3","title":"Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin","enrollment":31},{"nctId":"NCT04561115","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-09-02","conditions":"Primary Immunodeficiency","enrollment":33},{"nctId":"NCT00068055","phase":"PHASE1, PHASE2","title":"IVIG - West Nile Encephalitis: Safety and Efficacy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-09","conditions":"West Nile Virus","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IVIG-PEG","genericName":"IVIG-PEG","companyName":"Grifols Therapeutics LLC","companyId":"grifols-therapeutics-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"IVIG-PEG is a polyethylene glycol-conjugated intravenous immunoglobulin that provides passive immune protection by delivering pooled human antibodies with extended half-life. Used for Primary immunodeficiency disorders, Secondary immunodeficiency conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}